The landscape in medtech investing is changing, and one need only look at two signposts to see that this is so: the exit values of VC-backed companies over the past eight years (lower than anticipated), and the amount of time required to achieve those exits (longer than ever before). De Novo Ventures' Richard Ferrari presents the trends that emerge from eight years of venture investing in medical technology companies.

Cardiovascular Systems beat out 119 other suitors for the right to purchase publicly traded biopharma company, Replidyne, which had fallen on hard clinical times, or, more precisely, to acquire the company's place on the public markets. But now what? With CVS headed toward the public market, it will be interesting to see how the company is valued by public investors after its merger is complete. This month, we survey small cap medical device companies that are in similar situations to see how they're faring on the public markets.

Following the sale of Boston Scientific's venture portfolio, secondary buyers are positioning themselves as possible purchases of venture capital portfolios.